Onena Medicines
Onena Medicines is a biotech company leveraging cutting-edge AI technology to develop targeted antibody treatments for cancer, anemia, and obesity. They focus on neutralizing Dual SMAD Inhibiting Proteins (DSIPs), which are implicated in cancer cell growth and resistance to therapy. Their proprietary AI platform rapidly discovers neutralizing antibodies, even without crystal structures. The company aims to deliver a pipeline of first-in-class DSIP neutralizing molecules to the clinic. Onena Medicines is a spinout from Stanford University with headquarters in Switzerland and an R&D center in Spain. They have secured funding from various sources, including Avanteca Partners and Zürcher Kantonalbank, and have received grants such as Eureka Eurostars, NEOTEC, and HAZITEK, indicating significant traction and validation in their approach.
Onena Medicines
Onena Medicines is a biotech company leveraging cutting-edge AI technology to develop targeted antibody treatments for cancer, anemia, and obesity. They focus on neutralizing Dual SMAD Inhibiting Proteins (DSIPs), which are implicated in cancer cell growth and resistance to therapy. Their proprietary AI platform rapidly discovers neutralizing antibodies, even without crystal structures. The company aims to deliver a pipeline of first-in-class DSIP neutralizing molecules to the clinic. Onena Medicines is a spinout from Stanford University with headquarters in Switzerland and an R&D center in Spain. They have secured funding from various sources, including Avanteca Partners and Zürcher Kantonalbank, and have received grants such as Eureka Eurostars, NEOTEC, and HAZITEK, indicating significant traction and validation in their approach.
TL;DR
Headquarters: Allschwil, Switzerland
R&D: Donostia / San Sebastián, Spain
Technology: AI-driven antibody discovery targeting Dual SMAD Inhibiting Proteins (DSIPs)
Founded: 2019
Founders: Neethan Lobo; Maider Zabala
Employees (approx.): 10
Company Overview
Problem Domain
Antibody therapeutics for oncology and related indications (cancer, anemia, obesity) addressing DSIP-mediated biology.
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
3.7M CHF
Financing round announced to advance DSIP-targeting antibody portfolio
6413394 USD
Total funding amount reported
Investor Signal
“Received investment/support from BaseLaunch; listed investors and grant supporters include AVANTECA Partners, BaseLaunch, Centre for the Development of Industrial Technology (CDTI), Eurostars, MassChallenge, Plug and Play, Zürcher Kantonal Bank”